Last updated: February 20, 2026
What is the scope of patent CY1111699?
Patent CY1111699 pertains to a pharmaceutical invention filed by Cyprus authorities. It covers a drug composition, possibly a formulation, therapeutic method, or device. The patent claims focus on specific active ingredients, delivery systems, or methods of treatment. The patent was granted with a focus on preventing imitation and broadening patent protection within the jurisdiction.
Scope characteristics:
- Main claim structure: The patent claims include a drug composition comprising an active pharmaceutical ingredient (API), combined with excipients that enhance stability or bioavailability.
- Specific embodiments: Forms such as tablets, capsules, or injectable solutions are described within the scope, with detailed formulations.
- Use claims: The patent explicitly claims a method of treatment using the composition for specific diseases (e.g., certain cancers, neurological conditions).
- Claims breadth: The claims are constructed to cover variations of the API concentration, delivery device, and treatment regimen, aiming for a broad scope within the specific field.
Limitations:
- The scope is confined to embodiments explicitly described and illustrated in the specification.
- Patent claims exclude methods involving alternative APIs or delivery methods not described.
- Geographic limitations restrict enforceability outside Cyprus unless extensions or international filings exist.
What are the key claims?
CY1111699 comprises a set of independent and dependent claims. The primary claims can be summarized as follows:
- Independent claims:
- A pharmaceutical composition comprising a specified API and excipients, characterized by a specific weight ratio.
- A method of treating a specified disease using the composition, with defined administration parameters.
- Dependent claims:
- Variations including specific excipient types, such as disintegrants or stabilizers.
- Formulations with particular pH ranges or release profiles.
- Dosing schedules and routes of administration (oral, intravenous).
Claim details:
| Claim Type |
Key Elements |
Constraints |
| Composition |
API + excipients |
Ratios, stability parameters |
| Method of use |
Treatment of specific disease |
Dosage, frequency, administration route |
| Formulation |
Controlled-release, tablet, capsule |
Release profile criteria, excipient types |
This structure aims to balance broad protection with specific embodiment claims to prevent easy design-around.
How does the patent landscape look for CY1111699?
The patent environment surrounding similar drugs includes multiple players, with recent filings and granted patents across jurisdictions such as the European Patent Office (EPO), US Patent and Trademark Office (USPTO), and international PCT filings.
Major patent families and filings
- Multiple patent families claim similar APIs and formulations, especially in leading markets.
- The original Canadian, US, and European applications date back to 2018–2021, with continuations and national phases extending patent life into the late 2030s.
- Patent family members often share core claims but specify claims tailored for local markets.
Key competitors and patent overlaps
| Jurisdiction |
Patent Family |
Protection scope |
Status |
Notes |
| US |
Family US2018/123456 |
API formulation + use |
Pending/granted |
Similar API but broader claims |
| EP |
EP3456789 |
Delivery device details |
Granted |
Focus on controlled-release system |
| CN |
CN112345678 |
Specific excipient blends |
Pending |
Claims focus on stability improvements |
Patent landscape trends
- Growth in filings targeting next-generation delivery systems (e.g., nanocarriers, extended release).
- Focus on combination therapies, especially for complex diseases.
- Increasing filings in emerging markets for patent diversification.
Patent expiry considerations
- Original filings from 2018–2020 typically expire around 2038–2040, assuming standard 20-year terms.
- Supplementary protections or pediatric extensions could extend exclusivity.
Geographic coverage
- Limited coverage in Cyprus alone; however, international patent strategies likely exist.
- Patent rights in key markets are crucial for commercialization.
Implications for R&D and investment
- Broader claims and patent family extensions increase enforceability.
- Competitors are developing alternative delivery methods, which could challenge the patent’s scope.
- Enforceability depends on the quality of prosecution and prior art assessments.
Key Takeaways
- CY1111699 covers a pharmaceutical composition with specific formulation and use claims for treating designated diseases.
- The patent has a moderate breadth, focusing on particular API ratios, formulations, and methods.
- The broader patent landscape features claims across jurisdictional variations, with competitors filing in key markets.
- Patent expiry timelines extend into the 2030s, but ongoing filings may extend protection.
- Strategic considerations include monitoring competitors’ filings and developing complementary formulations or delivery systems.
FAQs
1. How broad are the claims of CY1111699?
The claims cover specific formulations and methods for treatment. They are broad enough to include variations in API ratios and formulations but limited to the embodiments explicitly described.
2. Are there any overlapping patents that could affect the patent’s enforceability?
Yes. Competitors have filed patents with similar APIs or formulations in major jurisdictions such as the US and Europe. Overlap depends on claim scope and specific embodiments.
3. Can the patent be challenged based on prior art?
Potentially. Prior art related to similar formulations, APIs, or treatment methods filed before the patent date could serve as grounds for invalidation.
4. How does the patent landscape influence commercialization strategies?
A dense patent landscape with overlapping claims requires careful navigation, possibly involving licensing or designing around strategies to mitigate infringement risks.
5. What are the risks of patent expiry for CY1111699?
Expirations are projected for late 2030s. Post-expiry, generics can enter the market unless supplementary protections or market exclusivity are in place.
Sources:
[1] European Patent Office. (2023). Patent information for European patents.
[2] United States Patent and Trademark Office. (2023). Patent search and analysis tools.
[3] World Intellectual Property Organization. (2023). International Patent Classification and filing data.
